Early Access — free while we kick the tires
EdgarHawk

FULC Fulcrum Therapeutics, Inc. Insider Trading

1 filing analyzed · Latest 2025-12-10
Insider buys
0
Insider sells
1
Unique insiders
1
Direction
Net selling

Historically, stocks have lagged the S&P 500 by a median ~4% over the 90 days after a high insider sell (n ≈ 9,950, 2021-2026). Past results don't predict the future. How we measure this ↗

December 2025
2025-12-10
high
4,175,139 shares
$58,377,021
@ $13.98
Significance 7/10

RA Capital Management sells 4,175,139 shares (4.18M) for $58,377,021.32, reducing stake 40.8% to 6,053,960 shares

RA Capital Management, a 10% owner, executed 3 separate sales totaling 4,175,139 shares for $58,377,021.32 on 2025-12-08, reducing holdings by 40.8% from 10,229,099 to 6,053,960 shares. The blended average sale price of $13.98 compares to current price of $13.80 (near the 52-week high of $14.60), and the stock has appreciated 79.9% over the past 30 days and 97.4% over the past 90 days following earlier losses. Fulcrum is pre-revenue (latest quarter $0.00) with a net loss of $19,595,000 for the full year, though annual revenue growth reached 2752.0% year-over-year. This large-scale reduction of a major stakeholder's position during a sharp recovery period merits scrutiny given the company's early-stage financial profile and the magnitude of the divestiture.

Insiders here also file at

More Chemicals and Allied Products companies

Get alerts for FULC

Add FULC to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access